NCT06789679View on ClinicalTrials.gov

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

January 25, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

Gemcitabine, albumin-bound paclitaxel, S-1

Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，q2w Gem：1000mg/m2，ivgtt，D1，q2w S-1：40-60mg Bid，PO，d1-7，q2w

DRUG

Gemcitabine, albumin-bound paclitaxel

Albumin-bound paclitaxel：125mg/m2，ivgtt，D1，D8，q3w Gem：1000mg/m2，ivgtt，D1，D8，q3w

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER